EMA Begins Rolling Review Of Remdesivir For COVID-19
Data To Be Reviewed As They Become Available
Results from the US ACCT study have led both the EMA and the FDA to accelerate the review of Gilead’s remdesivir for use in coronavirus patients. The EMA says it will also take account of the results of a Chinese study that found the antiviral was “not associated with statistically significant clinical benefits.”
